InteliCare Raises $1M to Extend Cash Runway and Scale Deployments
InteliCare Holdings has raised $1 million through a structured financing deal to extend its cash runway and scale its AI-driven healthcare platform across aged care and disability sectors.
- Secured $600,000 convertible note facility with 15% interest
- Obtained $400,000 R&D loan linked to claimable research spend
- Funding supports scaling deployments at Hardi Aged Care and mecwacare
- Convertible notes convert at $0.007 per share with attaching options
- Cash runway extended into 2026 to pursue sales pipeline opportunities
Funding Boost for AI-Driven Healthcare Platform
InteliCare Holdings Ltd, an Australian SaaS company specialising in AI-powered solutions for aged care and health sectors, has announced a $1 million funding package to support its ongoing commercial expansion. The structured financing comprises a $600,000 convertible note facility alongside a $400,000 research and development loan, providing the company with the financial runway to continue scaling its proprietary InteliCare platform into 2026.
Strategic Deployment and Commercial Momentum
The funding comes at a pivotal moment as InteliCare advances its largest deployment at Hardi Aged Care and prepares to launch a key trial at mecwacare’s Trescowthick facility. These deployments serve as critical proof points for the platform’s value proposition, which leverages smart sensors and AI to enhance care delivery and enable seniors to remain in their homes longer.
CEO Daniel Pilbrow emphasised the importance of the new capital in supporting existing projects while enabling the company to pursue additional contracts within its sales pipeline. The fresh funds also underpin ongoing strategic partnership discussions, signalling a period of accelerated growth and market engagement for InteliCare.
Convertible Notes and R&D Loan Details
The $600,000 convertible note facility allows InteliCare to draw funds in tranches of at least $50,000, with notes accruing 15% interest annually over a six-month term. Upon maturity, the notes and accrued interest are convertible into shares at $0.007 each, accompanied by unlisted options exercisable at $0.02. Shareholder approval will be sought to facilitate this conversion.
Complementing this, the $400,000 R&D loan from Rockford Equity Pty Ltd is secured against eligible research expenditure through the end of 2025. Rockford holds an option to convert up to half of this loan into shares under similar terms, subject to shareholder approval. These financing structures reflect a balanced approach to funding growth while managing dilution and investor alignment.
Looking Ahead
InteliCare’s ability to extend its cash runway into 2026 provides a crucial buffer to refine its technology, validate its commercial model, and deepen its market footprint. The company’s focus on AI-driven predictive analytics in healthcare positions it well amid growing demand for innovative aged care solutions. However, the success of upcoming shareholder approvals and the conversion of notes will be key milestones to watch as InteliCare navigates its next growth phase.
Bottom Line?
With fresh funding secured, InteliCare is poised to deepen its market presence, but shareholder approvals will be critical to unlocking full value.
Questions in the middle?
- Will shareholder approvals for note conversions proceed smoothly and on schedule?
- How quickly can InteliCare convert its sales pipeline into revenue-generating contracts?
- What impact will potential dilution from convertible notes and loan conversions have on share price?
